Contra-indicated in patients with existing QT prolongation, and in patients with liver disease.
Litt's app available free to subscribers - download for IOS and Android from the App Store or Google Play.
- TRADE NAME: Ranexa (CV Therapeutics)
- INDICATIONS: Angina
- CLASS: Anti-ischemic, Fatty acid oxidation inhibitor
- HALF-LIFE: 7 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Aprepitant, Atazanavir, Clarithromycin, Conivaptan, Cyclosporine, CYP3A inducers, CYP3A inhibitors, Darunavir, Delavirdine, Diltiazem, Dofetilide, Efavirenz, Erythromycin, Grapefruit Juice, Indinavir, Itraconazole, Ketoconazole, Lopinavir, Nelfinavir, Ombitasvir/Paritaprevir/Ritonavir, Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir, Oxcarbazepine, Paroxetine Hydrochloride, Phenobarbital, Quinidine, Rifampin, Rifapentine, Ritonavir, Simvastatin, Sotalol, Telithromycin, Thioridazine, Tipranavir, Venetoclax, Verapamil, Voriconazole, Ziprasidone
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
